Innovative design concepts in tumor-targeting peptide-drug conjugates: Insights into emerging applications
Peptide-drug conjugates (PDCs) have emerged as a promising strategy in cancer therapy, offering improved therapeutic efficacy and reduced toxicity. Compared to antibody-drug conjugates (ADCs) and small molecule-drug conjugates (SMDCs), PDCs possess distinct advantages, such as lower immunogenicity, improved tumor penetration, and simpler synthesis. This review discusses the latest advancements in PDC design, including novel peptide targeting mechanisms, linker selection, and formulation improvements for increased stability. Additionally, it explores the expanding clinical applications of PDCs and examines their limitations. The aim of this review is to provide a comprehensive overview of current PDC progress and outline future directions for their role in cancer treatment.
Authors
- Zijun Wu (ORCID: https://orcid.org/0000-0002-7847-4543)
- Xie Jun
- Ruirong Tan (ORCID: https://orcid.org/0000-0003-1719-1416)
- Shanshan Guo (ORCID: https://orcid.org/0000-0002-3880-4149)
- Hua Hua (ORCID: https://orcid.org/0000-0003-2245-0101)
- Zhujun Yin (ORCID: https://orcid.org/0000-0003-4489-1231)
- Miao Liu (ORCID: https://orcid.org/0000-0003-3365-0213)
- Li Li (ORCID: https://orcid.org/0000-0003-2247-5720)
- Rui Li (ORCID: https://orcid.org/0009-0006-8537-8783)
- Zhenya Yang
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Central South University (CN)
- University of Electronic Science and Technology of China (CN)
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
- Sichuan Academy of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Chinese Medical Journal
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1097/cm9.0000000000003438
- Citations
- 2
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 2.09